Bayer AG is not doing enough to help the NHS, the chief executive of the world’s largest pharmaceutical company told lawmakers Wednesday.
The comments came as the Senate Judiciary Committee released its annual report on the state of the federal antitrust system, which is being held in the Capitol building.
Bayer is one of the most powerful U.S. corporations, with a $15 billion market cap.
Its stock price is up more than 1,200 percent over the past year.
But the company is also struggling financially and the government is trying to cut its debt load.
The committee’s report paints a grim picture of the state-of-the-union, highlighting Bayer’s $1.5 trillion deficit, the company’s inability to develop a replacement for its cancer drug Orexigen and the ongoing battle with the Food and Drug Administration to regulate the use of its chemotherapy drug Abilify.
Berskaublik said the company was “not doing enough” to help patients, and noted that it was losing billions of dollars a year.
Berksaublak noted that in 2016, the United States spent more than $10 billion on lobbying for Bayer.
Bergmann’s $25 billion antitrust case against the FDA is also being heard in the Senate.